ReviewAsian journal of pharmaceutical sciences2026
Nanomaterials: An innovative integrative paradigm for hepatocellular carcinoma adjuvant treatment.
Review in Asian journal of pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review systematically examines the application of nanomaterials in adjuvant therapy for hepatocellular carcinoma (HCC) following surgical resection, with the aim of synergistically inhibiting tumor recurrence and driving functional liver regeneration via a 3R paradigm (removing residual tumor cells; remodeling the immune microenvironment; and repairing liver function). This article begins by analyzing the clinical challenges associated with treating HCC on the basis of global epidemiological data and the molecular characteristics of residual micrometastases after surgery. The concept of "precision space-time intervention" is then introduced, and the design strategies and clinical development of nanomaterials are explored, including targeting, biomimetic, sustained release and degradable designs. Furthermore, this review focuses on the postresection imbalance between tumor recurrence and tissue regeneration in the HCC microenvironment, elucidating the multiscale regulatory mechanisms of liver repair, such as cell differentiation, angiogenesis regulation, maintenance of the cellular redox balance, metabolic reprogramming, and modulation of the inflammatory microenvironment. The temporal dynamics of these mechanisms are emphasized, and the pivotal role of nanomaterials in this context is clarified. The key findings of this review indicate that a multimodal platform with nanomaterials as functional units can integrate diagnosis, hemostasis, antitumor activity and regeneration promotion, thereby overcoming the limitations of monotherapy, which cannot effectively cover the entire process of liver repair. This review breaks through the static intervention model of traditional adjuvant therapy, providing theoretical evidence for the development of multimodal sequential therapeutic nanoplatforms and outlining a clinical translation pathway from the validation of molecular mechanisms to GMP-standard production.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.